RHUDEX
DEAD

Serial Number

78285532

Owner

Avidex Limited

Attorney

Purvi J. Patel

Filing Date

Aug 11, 2003

Add to watchlist:

No watchlists yet
View on USPTO

RHUDEX Trademark

Serial Number: 78285532 • Registration: 2943640

RHUDEX is a trademark filed by Avidex Limited on August 11, 2003. The trademark is classified under Class 5 (Pharmaceuticals), Class 10 (Medical Apparatus), Class 42 (Computer & Scientific). The application is currently no longer active.

Owner Contact Info

Avidex Limited (8 trademarks)

57c Milton Park Abingdon
Oxfordshire OX14 4RX , GB

Entity Type: 11

MEDIGENE LIMITED (6 trademarks)

57C MILTON PARK
OXFORDSHIRE OX14 4RX , GB

Entity Type: 99

Trademark Details

Filing Date

August 11, 2003

Registration Date

April 26, 2005

Published for Opposition

February 1, 2005

Cancellation Date

September 28, 2012

Goods & Services

Antibodies, proteins, T cell proteins and peptides for medical use, monoclonal antibodies for clinical or medical use, pharmaceutical and biochemical substances and preparations, namely, small molecules, CD8O antagonists for the treatment of cancer, rheumatoid arthritis and auto-immune diseases; in vivo immunotherapeutic, immunoprophylactic and immunodiagnostic agents, preparations and substances for clinical or medical use; vaccines; protein conjugates; diagnostic and analytical preparations for medical and veterinary use, namely, products to diagnose and analyze tissue damage caused by inflammation due to auto-immune diseases; enzymes and enzyme preparations for clinical or medical use and the treatment of cancer, rheumatoid arthritis and auto-immune diseases; chemical products for use in medical science, namely, T-cell receptors, small molecule and protein therapeutics

Apparatus and instruments for diagnostic and therapeutic research, namely, instruments for measuring tissue damage or movement in limbs or organs; display apparatus, namely, multi-well plates and arrays for medical or clinical diagnosis and analysis; surgical and medical apparatus and instruments, namely, injectors, syringes, pre-filled vials containing pharmaceuticals and bioceuticals, namely small molecules and protein therapeutics involving T-cell receptors for the treatment of cancer, rheumatoid arthritis and auto-immune diseases

Biotechnology services, namely, the development of T-cell receptor pharmaceutical products and technologies for the treatment of cancer, rheumatoid arthritis, inflammatory and auto-immune diseases; scientific and medical research and development of new technology for others in the field of biotechnology and genomics, pharmaceutical drug development services, and pharmaceutical product development; genetic engineering services, licensing intellectual property namely, trademarks and patents in the field of biotechnology

Filing History

CANCELLED SEC. 8 (6-YR)
Sep 28, 2012 C8..
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Dec 17, 2008 TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Dec 17, 2008 TCCA
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Sep 19, 2007 ASGN
REGISTERED-PRINCIPAL REGISTER
Apr 26, 2005 R.PR
PUBLISHED FOR OPPOSITION
Feb 1, 2005 PUBO
NOTICE OF PUBLICATION
Jan 12, 2005 NPUB
LAW OFFICE PUBLICATION REVIEW COMPLETED
Nov 30, 2004 PREV
ASSIGNED TO LIE
Nov 29, 2004 ALIE
APPROVED FOR PUB - PRINCIPAL REGISTER
Nov 21, 2004 CNSA
AMENDMENT FROM APPLICANT ENTERED
Aug 30, 2004 ACEC
CORRESPONDENCE RECEIVED IN LAW OFFICE
Aug 5, 2004 CRFA
Sec. 1(B) CLAIM DELETED
Aug 5, 2004 1.BD
PAPER RECEIVED
Aug 5, 2004 MAIL
NON-FINAL ACTION MAILED
Feb 3, 2004 CNRT
ASSIGNED TO EXAMINER
Jan 24, 2004 DOCK